Alymsys (bevacizumab-maly) vs LY01008

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

Alymsys (bevacizumab-maly)

Marketed by Amneal Pharmaceuticals

Approved in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

LY01008

Marketed by Luye Pharma Group

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03533127 · Phase 3 · status unknown

This was a randomized, double-blind, active-controlled equivalence trial in 648 patients that measured objective tumor response rate, using the same paclitaxel/carboplatin backbone in both arms. LY01008's response rate was statistically equivalent to bevacizumab's, within the prespecified margin, meeting the trial's own equivalence criterion.

Reported efficacy

Best Objective Response Rate (19 weeks from randomization): LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated. (met)

Result source: NCT03533127

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlymsys (bevacizumab-maly)LY01008
PFS, median8.3 vs 8.6vs Avastinwk 52 · n 315NCT03296163—Not reported
OS, median—Not reported—Not reported
ORR40.3% vs 44.6%vs Avastinwk 18 · n 315NCT03296163—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

Alymsys (bevacizumab-maly)
8.3 vs 8.6vs Avastinwk 52 · n 315NCT03296163
LY01008
—Not reported

OS, median

Alymsys (bevacizumab-maly)
—Not reported
LY01008
—Not reported

ORR

Alymsys (bevacizumab-maly)
40.3% vs 44.6%vs Avastinwk 18 · n 315NCT03296163
LY01008
—Not reported

Duration of response, median

Alymsys (bevacizumab-maly)
—Not reported
LY01008
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

LY01008
LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated. NCT03533127 · Phase 3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Alymsys (bevacizumab-maly): 3 of 4 rows · LY01008: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlymsys (bevacizumab-maly)
Dropout rate
34.3%a
NCT03296163 · Phase 3
Discontinued due to AEs
—a
NCT03296163 · Phase 3
Serious AEs
18.6%a
NCT03296163 · Phase 3
Most frequent reported AEs
a
alopecia 49.8%
anemia 32.5%
nausea 15.1%
NCT03296163 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alymsys (bevacizumab-maly)

ORR 40.3% (n=315) vs 44.6% (n=312) Avastin @ 18wk
responder rate · % of participants
NCT03296163 · Phase 3
PFS 8.31 vs 8.61 Avastin months @ 52wk
time to event · months
NCT03296163 · Phase 3 · converted to months from 36 weeks as posted
Overall Survival NA vs NA Avastin months @ 52wk
time to event · months
NCT03296163 · Phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alymsys (bevacizumab-maly)'s landscape · LY01008's landscape